Skip to main
SANA

Sana Biotechnology (SANA) Stock Forecast & Price Target

Sana Biotechnology (SANA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sana Biotechnology Inc. is positioned favorably within the burgeoning biotechnology sector, highlighted by a substantial 32% growth in biologics usage from 2022 to 2023 across the U.S. and EU5 markets, indicating increasing demand for innovative therapies. The company's focus on developing engineered cell therapies, particularly with candidates like SG299, suggests that competitive advantages such as lower costs and enhanced accessibility could lead to better market uptake than traditional ex vivo cell therapies. This potential for growth in areas with unmet medical needs, coupled with a rising trend in biologics consumption, supports a positive outlook for Sana Biotechnology’s stock performance.

Bears say

Sana Biotechnology faces a negative outlook primarily due to uncertainties regarding the efficacy and safety of its lead programs, which could impede development and market acceptance. Furthermore, the high morbidity and mortality rates associated with conditions like lupus nephritis (LN) and Type 1 diabetes (T1D) pose significant challenges in establishing successful treatment outcomes. These fundamental issues raise concerns about the potential for sustainable revenue growth and the overall viability of its therapeutic endeavors.

Sana Biotechnology (SANA) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sana Biotechnology and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sana Biotechnology (SANA) Forecast

Analysts have given Sana Biotechnology (SANA) a Buy based on their latest research and market trends.

According to 8 analysts, Sana Biotechnology (SANA) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sana Biotechnology (SANA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.